dc.description.sponsorship |
3C. Three-City Study. The work was made possible by the participation of the control subjects, the
patients, and their families. We thank Dr. Anne Boland (CNG) for her technical help in preparing the DNA
samples for analyses. This work was supported by the National Foundation for Alzheimer’s disease and
related disorders, the Institut Pasteur de Lille and the Centre National de Génotypage. The 3C Study was
performed as part of a collaboration between the Institut National de la Santé et de la Recherche
Médicale (Inserm), the Victor Segalen Bordeaux II University and Sanofi-Synthélabo. The Fondation pour
la Recherche Médicale funded the preparation and initiation of the study. The 3C Study was also funded
by the Caisse Nationale Maladie des Travailleurs Salariés, Direction Générale de la Santé, MGEN, Institut
de la Longévité, Agence Française de Sécurité Sanitaire des Produits de Santé, the Aquitaine and
Bourgogne Regional Councils, Fondation de France and the joint French Ministry of Research/INSERM
“Cohortes et collections de données biologiques” programme. Lille Génopôle received an unconditional
grant from Eisai.
AGES. Age, Gene/Environment Susceptibility-Reykjavik Study. This study has been funded by NIH contract
N01-AG-1-2100, the NIA Intramural Research Program, Hjartavernd (the Icelandic Heart Association),
and the Althingi (the Icelandic Parliament). The study is approved by the Icelandic National Bioethics
Committee, VSN: 00-063. The researchers are indebted to the participants for their willingness to
participate in the study.
ARIC. Atherosclerosis Risk in Communities study. The ARIC study is carried out as a collaborative study
supported by National Heart, Lung, and Blood Institute contracts (HHSN268201100005C,
HHSN268201100006C, HHSN268201100007C, HHSN268201100008C, HHSN268201100009C,
HHSN268201100010C, HHSN268201100011C, and HHSN268201100012C), R01HL087641, R01HL59367
and R01HL086694; National Human Genome Research Institute contract U01HG004402; and National
Institutes of Health contract HHSN268200625226C. The authors thank the staff and participants of the
ARIC study for their important contributions. Infrastructure was partly supported by Grant Number
UL1RR025005, a component of the National Institutes of Health and NIH Roadmap for Medical Research.
This work as well as YL and AK were supported by the German Research Foundation (KO 3598/2-1, KO
3598/3-1 and CRC1140 A05 to AK).
ASPS. Austrian Stroke Prevention Study. The research reported in this article was funded by the Austrian
Science Fond (FWF) grant number P20545-P05 and P13180. The Medical University of Graz supports the
databank of the ASPS. The authors thank the staff and the participants of the ASPS for their valuable
contributions. We thank Birgit Reinhart for her long-term administrative commitment and Ing Johann
Semmler for the technical assistance at creating the DNA-bank.
BMES. Blue Mountains Eye Study. The BMES has been supported by the Australian RADGAC grant (1992-
94) and Australian National Health & Medical Research Council, Canberra Australia (Grant Nos: 974159,
211069, 991407, 457349). The GWAS studies of Blue Mountains Eye Study population are supported by
the Australian National Health & Medical Research Council (Grant Nos: 512423, 475604, 529912) and the
Wellcome Trust, UK (2008). EGH and JJW are funded by the Australian National Health & Medical
Research Council Fellowship Schemes.
CILENTO. Italian Network on Genetic Isolates – Cilento. We thank the populations of Cilento for their
participation in the study. The study was supported by the Italian Ministry of Universities and CNR
36
(PON03PE_00060_7, Interomics Flagship Project), the Assessorato Ricerca Regione Campania, the
Fondazione con il SUD (2011-PDR-13), and the Istituto Banco di Napoli - Fondazione to MC.
COLAUS. The CoLaus authors thank Yolande Barreau, Mathieu Firmann, Vladimir Mayor, Anne-Lise
Bastian, Binasa Ramic, Martine Moranville, Martine Baumer, Marcy Sagette, Jeanne Ecoffey and Sylvie
Mermoud for data collection. The CoLaus study received financial contributions from GlaxoSmithKline,
the Faculty of Biology and Medicine of Lausanne, the Swiss National Science Foundation (33CSCO-
122661, 3200BO-111361/2, 3100AO-116323/1, 310000-112552). The computations for CoLaus
imputation were performed in part at the Vital-IT center for high performance computing of the Swiss
Institute of Bioinformatics. We thank Vincent Mooser for his contribution to the CoLaus study.
EGCUT. Estonian Genome Center University of Tartu. EGCUT received financing from FP7 grants (278913,
306031, 313010) and targeted financing from Estonian Government (SF0180142s08). EGCUT studies
were covered from Infra-structure grant no. 3.2.0304.11-0312 funded mostly by the European Regional
Development Fund, Center of Excellence in Genomics (EXCEGEN) and University of Tartu (SP1GVARENG).
We acknowledge EGCUT technical personnel, especially Mr V. Soo and S. Smit. Data analyses were
carried out in part in the High Performance Computing Center of the University of Tartu.
FamHS. Family Heart Study. The FHS work was supported in part by NIH grants 5R01HL08770003,
5R01HL08821502 (Michael A. Province) from the NHLBI and 5R01DK07568102, 5R01DK06833603 from
the NIDDK (I.B.B.). The authors thank the staff and participants of the FamHS for their important
contributions.
FHS. Framingham Heart Study. This research was conducted in part using data and resources from the
Framingham Heart Study of the National Heart Lung and Blood Institute of the National Institutes of
Health and Boston University School of Medicine. The analyses reflect intellectual input and resource
development from the Framingham Heart Study investigators participating in the SNP Health Association
Resource (SHARe) project. This work was partially supported by the National Heart, Lung and Blood
Institute's Framingham Heart Study (Contract No. N01-HC-25195) and its contract with Affymetrix, Inc.
for genotyping services (Contract No. N02-HL-6-4278). A portion of this research utilized the Linux
Cluster for Genetic Analysis (LinGA-II) funded by the Robert Dawson Evans Endowment of the
Department of Medicine at Boston University School of Medicine and Boston Medical Center.
GENDIAN. GENetics of DIAbetic Nephropathy study. The support of the physicians, the patients, and the
staff of the Diabetes Zentrum Mergentheim (Head: Prof. Dr. Thomas Haak), the diabetes outpatient clinic
Dr Nusser - Dr Kreisel, the dialysis centers KfH Amberg, KfH Bayreuth, KfH Deggendorf, KfH Donauwörth,
KfH Freising, KfH Freyung, KfH Fürth, KfH Hof, KfH Ingolstadt, KfH Kelheim, KfH München
Elsenheimerstraße, KfH München-Schwabing, KfH Neumarkt, KfH Neusäß, KfH Oberschleißheim, KfH
Passau, KfH Plauen, KfH Regensburg Günzstraße, KfH Regensburg Caritas-Krankenhaus, KfH Straubing,
KfH Sulzbach-Rosenberg, KfH Weiden, Dialysezentrum Augsburg Dr. Kirschner, Dialysezentrum Bad
Alexandersbad, KfH Bamberg, Dialysezentrum Emmering, Dialysezentrum Klinikum Landshut,
Dialysezentrum Landshut, Dialysezentrum Pfarrkirchen, Dialysezentrum Schwandorf, Dr. Angela Götz,
the medical doctoral student Johanna Christ and the Study Nurse Ingrid Lugauer. The expert technical
assistance of Claudia Strohmeier is acknowledged. Phenotyping was funded by the Dr. Robert PflegerStiftung
(Dr Carsten A. Böger), the MSD Stipend Diabetes (Dr Carsten A. Böger) and the University
Hospital of Regensburg (intramural grant ReForM A to Dr. A. Götz, ReForM C to Dr. Carsten Böger).
Genome-wide genotyping was funded by the KfH Stiftung Präventivmedizin e.V. (Dr. Carsten A. Böger,
Dr. Jens Brüning), the Else Kröner-Fresenius-Stiftung (2012_A147 to Dr Carsten A. Böger and Dr Iris M.
Heid) and the University Hospital Regensburg (Dr Carsten A. Böger). Data analysis was funded by the Else
37
Kröner-Fresenius Stiftung (Dr. Iris M. Heid and Dr. Carsten A. Böger: 2012_A147; Dr. Carsten A. Böger
and Dr. Bernhard K. Krämer: P48/08//A11/08). GENDIAN Study Group: Mathias Gorski, Iris M. Heid,
Bernhard K. Krämer, Myriam Rheinberger, Michael Broll, Alexander Lammert, Jens Brüning, Matthias
Olden, Klaus Stark, Claudia Strohmeier, Simone Neumeier, Sarah Hufnagel, Petra Jackermeier, Emilia
Ruff, Johanna Christ, Peter Nürnberg, Thomas Haak, Carsten A. Böger.
HABC. Health Aging and Body Composition Study. The HABC study was funded by the National Institutes
of Aging. This research was supported by NIA contracts N01AG62101, N01AG62103, and N01AG62106.
The genome-wide association study was funded by NIA grant 1R01AG032098-01A1 to Wake Forest
University Health Sciences and genotyping services were provided by the Center for Inherited Disease
Research (CIDR). CIDR is fully funded through a federal contract from the National Institutes of Health to
The Johns Hopkins University, contract number HHSN268200782096C. This research was supported in
part by the Intramural Research Program of the NIH, National Institute on Aging.
HCS. Hunter Community Study. The University of Newcastle provided $300,000 from its Strategic
Initiatives Fund, and $600,000 from the Gladys M Brawn Senior Research Fellowship scheme; Vincent
Fairfax Family Foundation, a private philanthropic trust, provided $195,000; The Hunter Medical
Research Institute provided media support during the initial recruitment of participants; and Dr Anne
Crotty, Prof. Rodney Scott and Associate Prof. Levi provided financial support towards freezing costs for
the long-term storage of participant blood samples. The authors would like to thank the men and
women participating in the HCS as well as all the staff, investigators and collaborators who have
supported or been involved in the project to date. A special thank you should go to Alison Koschel and
Debbie Quain who were instrumental in setting up the pilot study and initial phase of the project.
HPFS. Health Professionals Follow-Up Study. The NHS/HPFS type 2 diabetes GWAS (U01HG004399) is a
component of a collaborative project that includes 13 other GWAS (U01HG004738, U01HG004422,
U01HG004402, U01HG004729, U01HG004726, U01HG004735, U01HG004415, U01HG004436,
U01HG004423, U01HG004728, RFAHG006033; National Institute of Dental & Craniofacial Research:
U01DE018993, U01DE018903) funded as part of the Gene Environment-Association Studies (GENEVA)
under the NIH Genes, Environment and Health Initiative (GEI). Assistance with phenotype harmonization
and genotype cleaning, as well as with general study coordination, was provided by the GENEVA
Coordinating Center (U01HG004446). Assistance with data cleaning was provided by the National Center
for Biotechnology Information. Genotyping was performed at the Broad Institute of MIT and Harvard,
with funding support from the NIH GEI (U01HG04424), and Johns Hopkins University Center for Inherited
Disease Research, with support from the NIH GEI (U01HG004438) and the NIH contract "High throughput
genotyping for studying the genetic contributions to human disease”(HHSN268200782096C). Additional
funding for the current research was provided by the National Cancer Institute (P01CA087969,
P01CA055075), and the National Institute of Diabetes and Digestive and Kidney Diseases (R01DK058845).
We thank the staff and participants of the NHS and HPFS for their dedication and commitment.
INGI-CARLANTINO. Italian Network on Genetic Isolates – Carlantino. We thank Anna Morgan and Angela
D’Eustacchio for technical support. We are grateful to the municipal administrators for their
collaboration on the project and for logistic support. We thank all participants to this study.
INGI-FVG. Italian Network on Genetic Isolates – Friuli Venezia-Giulia. We thank Anna Morgan and Angela
D’Eustacchio for technical support. We are grateful to the municipal administrators for their
collaboration on the project and for logistic support. We thank all participants to this study.
38
INGI-VAL BORBERA. Italian Network on Genetic Isolates – Val Borbera. We thank the inhabitants of the
Val Borbera who made this study possible, the local administrations and the ASL-Novi Ligure (Al) for
support. We also thank Clara Camaschella for data collection supervision and organization of the clinical
data collection, Fiammetta Vigano` for technical help and Corrado Masciullo for building the analysis
platform. The research was supported by funds from Compagnia di San Paolo, Torino, Italy; Fondazione
Cariplo, Italy and Ministry of Health, Ricerca Finalizzata 2008 and 2011/2012, CCM 2010, PRIN 2009 and
Telethon, Italy to DT.
IPM. Mount Sinai BioMe Biobank Program. The Mount Sinai BioMe Biobank Program is supported by The
Andrea and Charles Bronfman Philanthropies.
KORA-F3 and F4. The genetic epidemiological work was funded by the NIH subcontract from the
Children’s Hospital, Boston, US, (H.E.W., I.M.H, prime grant 1 R01 DK075787-01A1), the German National
Genome Research Net NGFN2 and NGFNplus (H.E.W. 01GS0823; WK project A3, number 01GS0834), the
Munich Center of Health Sciences (MC Health) as part of LMUinnovativ, and by the Else KrönerFresenius-Stiftung
(P48/08//A11/08; C.A.B., B.K.K; 2012_A147 to CAB and IMH.). The Genetic
Epidemiology at the University of Regensburg received financial contributions from the BMBF (01ER1206
and 01ER1507). The kidney parameter measurements in F3 were funded by the Else Kröner-FreseniusStiftung
(C.A.B., B.K.K.) and the Regensburg University Medical Center, Germany; in F4 by the University
of Ulm, Germany (W.K.). Genome wide genotyping costs in F3 and F4 were in part funded by the Else
Kröner-Fresenius-Stiftung (C.A.B., B.K.K.). De novo genotyping in F3 and F4 were funded by the Else
Kröner-Fresenius-Stiftung (C.A.B., B.K.K.). The KORA research platform and the MONICA Augsburg
studies were initiated and financed by the Helmholtz Zentrum München, German Research Center for
Environmental Health, by the German Federal Ministry of Education and Research and by the State of
Bavaria. Genotyping was performed in the Genome Analysis Center (GAC) of the Helmholtz Zentrum
München. The LINUX platform for computation were funded by the University of Regensburg for the
Department of Epidemiology and Preventive Medicine at the Regensburg University Medical Center.
LIFELINES. The authors wish to acknowledge the services of the Lifelines Cohort Study, the contributing
research centers delivering data to Lifelines, and all the study participants. Lifelines group authors:
Behrooz Z Alizadeh1
, H Marike Boezen1
, Lude Franke2
, Pim van der Harst3
, Gerjan Navis4
, Marianne Rots5
,
Harold Snieder1
, Morris Swertz2
, Bruce HR Wolffenbuttel6
and Cisca Wijmenga2
1. Department of Epidemiology, University of Groningen, University Medical Center Groningen, The
Netherlands
2. Department of Genetics, University of Groningen, University Medical Center Groningen, The
Netherlands
3. Department of Cardiology, University of Groningen, University Medical Center Groningen, The
Netherlands
4. Department of Internal Medicine, Division of Nephrology, University of Groningen, University Medical
Center Groningen, The Netherlands
5. Department of Medical Biology, University of Groningen, University Medical Center Groningen, The
Netherlands
6. Department of Endocrinology, University of Groningen, University Medical Center Groningen, The
Netherlands
MESA. Multi-Ethnic Study of Atherosclerosis. University of Washington (N01-HC-95159),Regents of the
University of California (N01-HC-95160), Columbia University (N01-HC-95161), Johns Hopkins University
39
(N01-HC-95162, N01-HC-95168), University of Minnesota (N01-HC-95163), Northwestern University
(N01-HC-95164), Wake Forest University (N01-HC-95165), University of Vermont (N01-HC-95166), New
England Medical Center (N01-HC-95167), Harbor-UCLA Research and Education Institute (N01-HC-
95169), Cedars-Sinai Medical Center (R01-HL-071205), University of Virginia (subcontract to R01-HL-
071205)
MICROS. Microisolates in South Tyrol study. We owe a debt of gratitude to all participants. We thank the
primary care practitioners R. Stocker, S. Waldner, T. Pizzecco, J. Plangger, U. Marcadent and the
personnel of the Hospital of Silandro (Department of Laboratory Medicine) for their participation and
collaboration in the research project. In South Tyrol, the study was supported by the Ministry of Health
and Department of Educational Assistance, University and Research of the Autonomous Province of
Bolzano, the South Tyrolean Sparkasse Foundation, and the European Union framework program 6
EUROSPAN project (contract no. LSHG-CT-2006-018947).
NESDA. The Netherlands Study of Depression and Anxiety. The infrastructure for the NESDA study is
funded through the Geestkracht programme of the Dutch Scientific Organization (ZON-MW, grant
number 10-000-1002) and matching funds from participating universities and mental health care
organizations. Genotyping in NESDA was funded by the Genetic Association Information Network (GAIN)
of the Foundation for the US National Institutes of Health.
NHS. Nurses' Health Study. The NHS/HPFS type 2 diabetes GWAS (U01HG004399) is a component of a
collaborative project that includes 13 other GWAS (U01HG004738, U01HG004422, U01HG004402,
U01HG004729, U01HG004726, U01HG004735, U01HG004415, U01HG004436, U01HG004423,
U01HG004728, RFAHG006033; National Institute of Dental & Craniofacial Research: U01DE018993,
U01DE018903) funded as part of the Gene Environment-Association Studies (GENEVA) under the NIH
Genes, Environment and Health Initiative (GEI). Assistance with phenotype harmonization and genotype
cleaning, as well as with general study coordination, was provided by the GENEVA Coordinating Center
(U01HG004446). Assistance with data cleaning was provided by the National Center for Biotechnology
Information. Genotyping was performed at the Broad Institute of MIT and Harvard, with funding support
from the NIH GEI (U01HG04424), and Johns Hopkins University Center for Inherited Disease Research,
with support from the NIH GEI (U01HG004438) and the NIH contract "High throughput genotyping for
studying the genetic contributions to human disease”(HHSN268200782096C). The NHS renal function
and albuminuria work was supported by DK66574. Additional funding for the current research was
provided by the National Cancer Institute (P01CA087969, P01CA055075), and the National Institute of
Diabetes and Digestive and Kidney Diseases (R01DK058845). We thank the staff and participants of the
NHS and HPFS for their dedication and commitment.
NSPHS. The Northern Swedish Population Health Study. The NSPHS was supported by grants from the
Swedish Natural Sciences Research Council, the European Union through the EUROSPAN project
(contract no. LSHG-CT-2006-018947), the Foundation for Strategic Research (SSF) and the Linneaus
Centre for Bioinformatics (LCB). We are also grateful for the contribution of samples from the Medical
Biobank in Umeå and for the contribution of the district nurse Svea Hennix in the Karesuando study.
RS-I. The Rotterdam Study. The GWA study was funded by the Netherlands Organisation of Scientific
Research NWO Investments (nr. 175.010.2005.011, 911-03-012), the Research Institute for Diseases in
the Elderly (014-93-015; RIDE2), the Netherlands Genomics Initiative (NGI)/Netherlands Consortium for
Healthy Aging (NCHA) project nr. 050-060-810. We thank Pascal Arp, Mila Jhamai, Dr Michael
40
Moorhouse, Marijn Verkerk, and Sander Bervoets for their help in creating the GWAS database. The
Rotterdam Study is funded by Erasmus Medical Center and Erasmus University, Rotterdam, Netherlands
Organization for the Health Research and Development (ZonMw), the Research Institute for Diseases in
the Elderly (RIDE), the Ministry of Education, Culture and Science, the Ministry for Health, Welfare and
Sports, the European Commission (DG XII), and the Municipality of Rotterdam. The authors are very
grateful to the participants and staff from the Rotterdam Study, the participating general practitioners
and the pharmacists. We would like to thank Dr. Tobias A. Knoch, Luc V. de Zeeuw, Anis Abuseiris, and
Rob de Graaf as well as their institutions the Erasmus Computing Grid, Rotterdam, The Netherlands, and
especially the national German MediGRID and Services@MediGRID part of the German D-Grid, both
funded by the German Bundesministerium fuer Forschung und Technology under grants #01 AK 803 A-H
and # 01 IG 07015 G, for access to their grid resources. Abbas Dehghan is supported by NWO grant (vici,
918-76-619).
SAPALDIA. Swiss Study on Air Pollution and Lung Diseases in Adults. The SAPALDIA Team: Study
directorate: T Rochat (p), NM Probst Hensch (e/g), N Künzli (e/exp), C Schindler (s), JM Gaspoz (c)
Scientific team: JC Barthélémy (c), W Berger (g), R Bettschart (p), A Bircher (a), O Brändli (p), C Brombach
(n), M Brutsche (p), L Burdet (p), M Frey (p), U Frey (pd), MW Gerbase (p), D Gold (e/c/p), E de Groot (c),
W Karrer (p), R Keller (p), B Martin (pa), D Miedinger (o), U Neu (exp), L Nicod (p), M Pons (p), F Roche
(c), T Rothe (p), E Russi (p), P Schmid-Grendelmeyer (a), A Schmidt-Trucksäss (pa), A Turk (p), J Schwartz
(e), D. Stolz (p), P Straehl (exp), JM Tschopp (p), A von Eckardstein (cc), E Zemp Stutz (e). Scientific team
at coordinating centers: M Adam (e/g), C Autenrieth (pa), PO Bridevaux (p), D Carballo (c), E Corradi
(exp), I Curjuric (e), J Dratva (e), A Di Pasquale (s), E Dupuis Lozeron (s), E Fischer (e), M Germond (s), L
Grize (s), D Keidel (s), S Kriemler (pa), A Kumar (g), M Imboden (g), N Maire (s), A Mehta (e), H Phuleria
(exp), E Schaffner (s), GA Thun (g) A Ineichen (exp), M Ragettli (e), M Ritter (exp), T Schikowski (e), M
Tarantino (s), M Tsai (exp) (a) allergology, (c) cardiology, (cc) clinical chemistry, (e) epidemiology, (exp)
exposure, (g) genetic and molecular biology, (m) meteorology, (n) nutrition, (o) occupational health, (p)
pneumology, (pa) physical activity, (pd) pediatrics, (s) statistics. Funding: The Swiss National Science
Foundation (grants no 33CSCO-134276/1, 33CSCO-108796, 3247BO-104283, 3247BO-104288, 3247BO-
104284, 3247-065896, 3100-059302, 3200-052720, 3200-042532, 4026-028099), the Federal Office for
Forest, Environment and Landscape, the Federal Office of Public Health, the Federal Office of Roads and
Transport, the canton's government of Aargau, Basel-Stadt, Basel-Land, Geneva, Luzern, Ticino, Valais,
and Zürich, the Swiss Lung League, the canton's Lung League of Basel Stadt/ Basel Landschaft, Geneva,
Ticino, Valais and Zurich, SUVA, Freiwillige Akademische Gesellschaft, UBS Wealth Foundation, Talecris
Biotherapeutics GmbH, Abbott Diagnostics, European Commission 018996 (GABRIEL), Wellcome Trust
WT 084703MA. The study could not have been done without the help of the study participants, technical
and administrative support and the medical teams and field workers at the local study sites. Local
fieldworkers : Aarau: S Brun, G Giger, M Sperisen, M Stahel, Basel: C Bürli, C Dahler, N Oertli, I Harreh, F
Karrer, G Novicic, N Wyttenbacher, Davos: A Saner, P Senn, R Winzeler, Geneva: F Bonfils, B Blicharz, C
Landolt, J Rochat, Lugano: S Boccia, E Gehrig, MT Mandia, G Solari, B Viscardi, Montana: AP Bieri, C
Darioly, M Maire, Payerne: F Ding, P Danieli A Vonnez, Wald: D Bodmer, E Hochstrasser, R Kunz, C Meier,
J Rakic, U Schafroth, A Walder. Administrative staff: C Gabriel, R Gutknecht.
SHIP and SHIP-TREND. The Study of Health in Pomerania. SHIP is part of the Community Medicine
Research net of the University of Greifswald, Germany, which is funded by the Federal Ministry of
Education and Research (grants no. 01ZZ9603, 01ZZ0103, and 01ZZ0403), the Ministry of Cultural Affairs
as well as the Social Ministry of the Federal State of Mecklenburg-West Pomerania, and the network
41
‘Greifswald Approach to Individualized Medicine (GANI_MED)’ funded by the Federal Ministry of
Education and Research (grant 03IS2061A). Genome-wide data have been supported by the Federal
Ministry of Education and Research (grant no. 03ZIK012) and a joint grant from Siemens Healthcare,
Erlangen, Germany and the Federal State of Mecklenburg- West Pomerania. The University of Greifswald
is a member of the ‘Center of Knowledge Interchange’ program of the Siemens AG and the Caché
Campus program of the InterSystems GmbH. The SHIP authors are grateful to Mario Stanke for the
opportunity to use his Server Cluster for the SNP imputation as well as to Holger Prokisch and Thomas
Meitinger (Helmholtz Zentrum München) for the genotyping of the SHIP-TREND cohort.
TRAILS. TRacking Adolescents' Individual Lives. Trails is a collaborative project involving various
departments of the University Medical Center and University of Groningen, the Erasmus University
Medical Center Rotterdam, the University of Utrecht, the Radboud Medical Center Nijmegen, and the
Parnassia Bavo group, all in the Netherlands. TRAILS has been financially supported by grants from the
Netherlands Organization for Scientific Research NWO (Medical Research Council program grant GB-MW
940-38-011; ZonMW Brainpower grant 100-001-004; ZonMw Risk Behavior and Dependence grants 60-
60600-98-018 and 60-60600-97-118; ZonMw Culture and Health grant 261-98-710; Social Sciences
Council medium-sized investment grants GB-MaGW 480-01-006 and GB-MaGW 480-07-001; Social
Sciences Council project grants GB-MaGW 457-03-018, GB-MaGW 452-04-314, and GB-MaGW 452-06-
004; NWO large-sized investment grant 175.010.2003.005; NWO Longitudinal Survey and Panel Funding
481-08-013); the Sophia Foundation for Medical Research (projects 301 and 393), the Dutch Ministry of
Justice (WODC), the European Science Foundation (EuroSTRESS project FP-006), and the participating
universities. We are grateful to all adolescents, their parents and teachers who participated in this
research and to everyone who worked on this project and made it possible. Statistical analyses were
carried out on the Genetic Cluster Computer (http://www.geneticcluster.org), which is financially
supported by the Netherlands Scientific Organization (NWO 480-05-003) along with a supplement from
the Dutch Brain Foundation.
WGHS. Women’s Genome Health Study. The WGHS is supported by the National Heart, Lung, and Blood
Institute (HL043851 and HL080467) and the National Cancer Institute (CA047988 and UM1CA182913),
with collaborative scientific support and funding for genotyping provided by Amgen.
YFS. Young Finns Study. The YFS has been financially supported by the Academy of Finland: grants
134309 (Eye), 126925, 121584, 124282, 129378 (Salve), 117787 (Gendi), and 41071 (Skidi), the Social
Insurance Institution of Finland, Kuopio, Tampere and Turku University Hospital Medical Funds (grant
9M048 and 9N035 for TeLeht), Juho Vainio Foundation, Paavo Nurmi Foundation, Finnish Foundation of
Cardiovascular Research and Finnish Cultural Foundation, Tampere Tuberculosis Foundation and Emil
Aaltonen Foundation (T.L). The technical assistance in the statistical analyses by Ville Aalto and Irina
Lisinen is acknowledged. |